Business Wire

GA-ADVA

5.10.2021 09:02:07 CEST | Business Wire | Press release

Share
ADVA protects critical network infrastructure with new end-to-end assured PNT solution

ADVA (FSE: ADV) today announced that it has responded to calls from the US Department of Homeland Security (DHS) and National Institute of Standards and Technology (NIST) to protect critical infrastructure from the growing danger of GNSS vulnerabilities and cyber threats to positioning, navigation and timing (PNT) services with the launch of its aPNT+™ platform . This scalable solution meets all the latest guidelines for resilient PNT and is the industry’s most complete offering. It provides end-to-end control and timing network visibility for the most robust protection available against the catastrophic risks that PNT disruption poses to national security and essential assets such as power grids.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005061/en/

“Cyber threats are at an all-time high. At the same time, the infrastructure that our economies and lives depend on has never been more reliant on weak and highly vulnerable satellite signals. That’s why the US DHS and NIST are driving for PNT services to be more resilient and for network operators to implement strategies to counteract the vulnerabilities of GPS and other GNSS systems, including in-network PTP timing feeds. Our trusted aPNT+ platform is the definitive response. Being open and scalable, it offers an end-to-end range of cost-effective solutions and the industry’s most comprehensive features for augmented resilience, robustness and cybersecurity,” said Gil Biran, general manager, Oscilloquartz, ADVA. “For industries and governments, timing is now a critical service in need of urgent protection. Our aPNT+ platform will be the cornerstone of the most effective defense in depth strategies.”

Governments worldwide have issued guidelines to protect businesses and society from disruption to PNT services, including US Executive Order 13905, which was followed by the DHS Resilient PNT Conformance Framework and NIST Cybersecurity Framework for PNT Profile. The guidelines urge operators to swiftly implement technologies and measures to safeguard vital infrastructure. Based on these, ADVA has integrated an intelligent and scalable aPNT platform into its product portfolio. Even without GPS or GNSS timing, the solution provides an intelligent, end-to-end self-recovery system designed around a threefold framework. Integrating sophisticated multi-layer detection, multi-source backup and multi-level fault-tolerant mitigation, it delivers the highest levels of resilience, robustness and cybersecurity. This is a new standard for assured PNT services, integrating not only the DHS framework’s four levels of PNT resilience but also providing enhanced level four resilience, the highest level for trusted PNT services assurance.

“Our aPNT+ platform will be invaluable for any critical infrastructure with a crucial dependence on PNT services. With our wide-ranging product portfolio, it offers all the building blocks to create an end-to-end solution, including advanced cesium clocks, our extensive family of PTP grandmasters from core to miniature, and our innovative sync assurance application,” said Nino De Falcis, senior director, business development, Oscilloquartz, ADVA. “From transportation to national defense, from energy to finance, today’s industries need to take action against the enormous risk to lives and livelihoods that reliance on PNT represents. Now there’s a new trusted way to prevent, respond and recover PNT services against disruption with our comprehensive aPNT+ solution.”

Further details on ADVA’s aPNT+ platform can be found in this guide: https://adva.li/apnt-sync-guide .

Supporting slides can be viewed here: https://adva.li/apnt-slides .


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye